NasdaqGS - Nasdaq Real Time Price USD

Vaxcyte, Inc. (PCVX)

29.00

-0.24

(-0.82%)

At close: May 7 at 4:00:01 PM EDT

29.10

+0.10

+(0.34%)

Pre-Market: 5:00:38 AM EDT

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal

GlobeNewswire 13 hours ago

PCVX
-0.82%
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. “We are thrilled to welcome Olivier to Vaxcyte’s Board of Directors,” said Grant Pickering, Chief Ex

GlobeNewswire 6 days ago

PCVX
-0.82%
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against other oversold NASDAQ stocks to buy right now. On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on CNBC’s ‘Squawk […]

Insider Monkey 8 days ago

PCVX
-0.82%
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 21 days ago

PCVX
-0.82%
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential

We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street is overflowing with data. If companies are not […]

Insider Monkey 26 days ago

PCVX
-0.82%
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Zacks 27 days ago

PCVX
-0.82%

PFE
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI

Evercore ISI notes that Vaxcyte (PCVX) missed four serotypes versus Prevnar20 in the “all-important” infant data, adding that an “imperfect vaccine press release on the heels of Peter Marks resignation is just tough timing.” However, the analyst contends that three of the four misses in today’s Phase 2 are “narrow – and will quite likely be ok” in a larger Phase 3 trial. The firm maintains an Outperform rating on Vaxcyte shares, which are down $34.89, or 50%, to $34.57 in early afternoon trading

TipRanks last month

PCVX
-0.82%
Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

The major averages were mostly lower near noon, with the Dow up fractionally but the Nasdaq down nearly 250 points amid mounting concerns about President Donald Trump’s upcoming announcement of promised new tariffs. Meanwhile, the S&P 500’s early losses brought the index to its lowest level since September. Looking to commodities, gold prices are sharply higher, continuing their rally to over $3,150, while oil prices are also up over 2.5%. Get caught up quickly on the top news and calls moving s

TipRanks last month

GT

MU

HUT
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

Zacks last month

PCVX
-0.82%
Vaxcyte stock sinks despite Phase II IPD vaccine trial success

Vaxcyte is awaiting data from another candidate before advancing to Phase III.

Clinical Trials Arena last month

PCVX
-0.82%

GLDAF
Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.

Investor's Business Daily last month

MRNA

PCVX
-0.82%

SRPT
Moderna, biotech stocks slide following resignation of FDA official Peter Marks

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.

Yahoo Finance last month

DVAX

PCVX
-0.82%

NVAX
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says

Vaxcyte's (PCVX) results for vaccine candidate VAX-24 came in below some Wall Street expectations bu

PREMIUM
MT Newswires last month

PCVX
-0.82%
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Suppo

GlobeNewswire last month

PCVX
-0.82%
Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other debt free mid cap stocks. Debt-free mid-cap stocks currently offer compelling investment opportunities, especially in today’s high-interest-rate environment. With […]

Insider Monkey last month

PCVX
-0.82%
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s

GlobeNewswire last month

PCVX
-0.82%
Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care equity […]

Insider Monkey last month

PCVX
-0.82%
Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

We recently published a list of the 12 Best Up and Coming Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against other up and coming stocks to buy according to Wall Street Analysts. Tom Lee, Fundstrat managing partner, joined […]

Insider Monkey last month

PCVX
-0.82%
Vaxcyte (PCVX) Struggled Amid Political Uncertainty

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Small-cap stocks had mixed results in the fourth quarter, failing to match their previous quarter’s rebound. The Russell 2000® Growth Index rose 1.70%, outperforming the Russell […]

Insider Monkey last month

PCVX
-0.82%

^RUT
Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

The markets have been volatile recently as economic uncertainty and tariff threats have rattled investors. Yet, despite the concerns, Goldman Sachs’ chief US equity strategist David Kostin sees reason for long-term optimism – and makes some concrete recommendations about where investors should put their funds to cash in. Simply put, Kostin believes that healthcare stocks are the way to go in 2025. Healthcare makes up more than 17% of the total US economy, and it has a defensive tilt – even if ti

TipRanks last month

MDGL

PCVX
-0.82%

Performance Overview

Return	PCVX	S&P 500 (^GSPC)
YTD	-64.57%	-4.26%
1-Year	-57.05%	+8.55%
3-Year	+19.49%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vaxcyte, Inc. (PCVX)

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

Vaxcyte stock sinks despite Phase II IPD vaccine trial success

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Moderna, biotech stocks slide following resignation of FDA official Peter Marks

Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy

Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

Vaxcyte (PCVX) Struggled Amid Political Uncertainty

Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now

Performance Overview